Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
4 NC counties are under alert, including Edgecombe County.
Breaking News
Fayetteville police respond to massive fight involving 50 juveniles at Cross Creek Mall
Program
On WRAL at 11: A live report from WRAL's Liz McLaughlin in Paris: How Team USA won their first gold medal today.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
110.32
+0.39 (+0.35%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
Cardiff Oncology is a prime takeover target heading into 2022.
Via
The Motley Fool
Exposures
COVID-19
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?
November 16, 2021
Molecular Partners AG (NASDAQ: MOLN) has announced that a planned futility analysis of ensovibep in the Phase 3 ACTIV-3 study has not met the thresholds required to continue...
Via
Benzinga
Earnings Scheduled For October 26, 2021
October 26, 2021
Companies Reporting Before The Bell • Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million. • Aarons (NYSE:AAN)...
Via
Benzinga
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
November 12, 2021
Johnson & Johnson will split its consumer health unit into a publicly traded company.
Via
Investor's Business Daily
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
November 11, 2021
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
The Old Lady Of Threadneedle Street
November 05, 2021
US markets are up on better jobs growth reported for October today.
Via
Talk Markets
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
November 05, 2021
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Why Did Deciphera Stock Plunged 70% Today?
November 05, 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in...
Via
Benzinga
64 Stocks Moving In Friday's Mid-Day Session
November 05, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...
Via
Benzinga
Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial
November 04, 2021
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active...
Via
Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...
Via
Benzinga
Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad
November 02, 2021
The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally...
Via
Benzinga
FDA Approves Novartis' Scemblix In Two Chronic Myeloid Leukemia Settings
November 01, 2021
The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications. The FDA granted...
Via
Benzinga
Exposures
Product Safety
Tuesday Market Coverage
October 26, 2021
Thermo Electron fell on the publication of its social responsibility report today.
Via
Talk Markets
Novartis (NVS) Q3 2021 Earnings Call Transcript
October 26, 2021
NVS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Novartis Boosts Guidance For These Key Drugs After Their Bang-Up Quarter
October 26, 2021
Novartis stock inched higher Tuesday after the company reported a mixed third quarter, but increased guidance for two drugs.
Via
Investor's Business Daily
Novartis: Q3 Earnings Insights
October 26, 2021
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 26, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
October 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...
Via
Benzinga
Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook
October 26, 2021
Novartis AG (NYSE: NVS) reported that its Q3 net income climbed 43% to $2.76 billion. EPS reached $1.23, up 45% Y/Y. Earnings: The Company posted a core EPS of $1.71,...
Via
Benzinga
Cyber Currency
October 26, 2021
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.
Via
Talk Markets
A Preview Of Novartis's Earnings
October 25, 2021
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2021-10-26. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Price To Earnings Ratio Insights For Novartis
October 22, 2021
In the current market session, Novartis Inc. (NYSE:NVS) is trading at $84.51, after a 0.19% decrease. However, over the past month, the stock increased by 1.91%, and...
Via
Benzinga
Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines
October 21, 2021
Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19...
Via
Benzinga
Exposures
COVID-19
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
October 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.